Clinical Trial Update: Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial update reports safety and tolerability findings for RGX-314 gene therapy in neovascular age-related macular degeneration, with trial status co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Drugs mentioned

• RGX-314

Snippet

Sponsor: REGENXBIO Inc. | Conditions: Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-05-16